Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that psychiatric adverse drug reactions were more frequently reported with finasteride than with dutasteride, but it remains unclear if there is a causal relationship.

This study reviewed human evidence on the effects of 5α-reductase inhibitors, finasteride and dutasteride, on semen parameters and gonadotrophins, finding finasteride causes mild, reversible changes, while dutasteride may lead to more pronounced and potentially less reversible impacts, suggesting caution for those planning to conceive.

Finasteride and dutasteride may increase the risk of suicide and sexual dysfunction.

This study found that long-term use of 5α-reductase inhibitors is associated with improved overall survival in men with renal cell carcinoma, particularly those with low comorbidity not receiving surgery or systemic therapy, suggesting a potential role for androgen modulation in disease management.

This study found that combining platelet-rich plasma with systemic therapies for androgenetic alopecia may result in greater improvements in hair density and width than using PRP alone, though the differences were not statistically significant.

This review reports that 5-alpha reductase inhibitors, used to treat androgenic alopecia, may adversely affect sperm count, sexual function, and hormones in a subset of patients.

This study found that prolonged use of finasteride and dutasteride in young men with androgenic alopecia is linked to a decline in semen quality over time, particularly affecting sperm motility and DNA integrity, with dutasteride showing a slightly greater impact than finasteride.

This pharmacovigilance study analyzed FAERS data and found that finasteride is more frequently associated with neuropsychiatric reactions like depression and suicide risk, especially in younger men using it for alopecia, compared to dutasteride.

In this study, dermatologists in Spain reported a shift in androgenetic alopecia treatment practices from 2019-2020 to 2024, with increased prescribing of oral minoxidil and oral dutasteride, and changes in antiandrogen choices for different patient groups.

Spironolactone is effective for treating female hair loss, with new treatments like clascoterone showing promise.

This systematic review synthesizes evidence on the distribution of 5a-reductase isozymes and their implications for mental health, finding that inhibition of neurosteroidogenesis may contribute to anxiety, depression, and suicidality, with some patients experiencing persistent psychiatric effects from finasteride or dutasteride.

This study found that Adapalene, Diosmin, and Azelastine have potential as multi-target drugs against Onchocerca volvulus and its endosymbiont, which might offer new therapeutic options for treating river blindness, but further research is needed to confirm their effectiveness.

This study used molecular docking simulations to identify Adapalene, Diosmin, and Azelastine as promising drugs for repurposing against Onchocerciasis by targeting Onchocerca volvulus and its endosymbiont; further research is suggested to confirm their efficacy.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

This study used molecular docking simulations to identify Adapalene, Diosmin, and Azelastine as promising drugs for repurposing against onchocerciasis by targeting proteins in the parasite and its endosymbiont; further research is needed to confirm their efficacy.

Both finasteride and dutasteride can cause sexual side effects, but they may differ in frequency and severity.

The researchers reported that oral finasteride 1 mg was associated with more frequent reports of sexual adverse events than dutasteride 0.5 mg, particularly after 2012, which may be influenced by the nocebo effect.

According to this study, daily use of dutasteride 0.5 mg is the most effective treatment for male androgenic hair loss, while topical minoxidil serves as a viable alternative; combination treatments improve results, but more research is needed across various patient groups.

In this study, researchers found that dutasteride 0.5 mg/day is the most effective treatment for male androgenic alopecia, with topical minoxidil also being a viable option. Combination treatments improve outcomes, but further research is needed to evaluate efficacy across diverse patient groups.

5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.

Finasteride and dutasteride have little effect on Type 2 Diabetes risk.

Finasteride and dutasteride may increase the risk of depression and suicidality, so patients should be monitored closely.

In this randomized study, intradermal injections of dutasteride effectively improved androgenetic alopecia in 15 male patients, showing significant clinical improvement within one month and being well-tolerated without notable side effects, though the improvement was negatively correlated with longer disease duration.

The MHRA announced on 11 May 2026 that it will update the product information for finasteride and dutasteride to include more details on potential psychiatric and sexual side effects, following a review of existing evidence.

This review indicates that while microneedling shows potential for managing androgenetic alopecia, particularly in combination with other treatments, the existing evidence is of low to moderate quality, and more robust trials are needed to confirm its clinical efficacy and safety.

In this study, both finasteride and dutasteride were effective for androgenetic alopecia, but dutasteride significantly improved hair density more than finasteride and had a comparable safety profile among men treated at an Indian center.

In this study, the authors concluded that there is no clear difference in suicidal ideation between different 5α-reductase inhibitors, but results vary by finasteride dose, patient age, and psychiatric history.

Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.

This review synthesizes recent advancements in clinical trichology, highlighting updates on androgenetic alopecia treatments like low-dose oral minoxidil, 5α-reductase inhibitors, and other therapeutic options for various alopecia types, including telogen/anagen effluvium and alopecia areata, and detailed approaches for scarring alopecias and pediatric trichology.